Endoxifen's Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Hawse, John R ^a   Subramaniam, Malayannan ^a   Cicek, Muzaffer ^a   Wu, Xianglin ^a   Gingery, Anne ^a   Grygo, Sarah B ^a   Sun, Zhifu ^b   Pitel, Kevin S ^a   Lingle, Wilma L ^b   Goetz, Matthew P ^b   Ingle, James N ^b   Spelsberg, Thomas C ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; CELL MARKER; DRUG METABOLITE; ENDOXIFEN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; TRANSCRIPTOME;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ESTROGEN RECEPTOR ALPHA GENE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE TARGETING; NUCLEOTIDE SEQUENCE; PROTEIN DNA BINDING; SIGNAL TRANSDUCTION; UPREGULATION;

BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CLUSTER ANALYSIS; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84873851224     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054613     Document Type: Article

References (23)

1. Clarke R, Leonessa F, Welch JN, Skaar TC, (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53: 25-71.
2. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351: 1451-1467.
3. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 365: 1687-1717.
4. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (2004) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. 1992. Br J Clin Pharmacol 58: S744-747; discussion 748-750.
5. Desta Z, Ward BA, Soukhova NV, Flockhart DA, (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310: 1062-1075.
6. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, et al. (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95: 1758-1764.
7. Borgna JL, Rochefort H, (1981) Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem 256: 859-868.
8. Coezy E, Borgna JL, Rochefort H, (1982) Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42: 317-323.
9. Jordan VC, (1982) Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat 2: 123-138.
10. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF, (1984) Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44: 112-119.
11. Borges S, Desta Z, Li L, Skaar TC, Ward BA, et al. (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80: 61-74.
12. Mauvais-Javis P, Baudot N, Castaigne D, Banzet P, Kuttenn F, (1986) trans-4-Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast. Cancer Res 46: 1521-1525.
13. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, et al. (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85: 151-159.
14. Lim YC, Desta Z, Flockhart DA, Skaar TC, (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55: 471-478.
15. Lim YC, Li L, Desta Z, Zhao Q, Rae JM, et al. (2006) Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 318: 503-512.
16. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, et al. (2009) The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69: 1722-1727.
17. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, et al. (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clinical pharmacology and therapeutics 89: 718-725.
18. Osborne CK, (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618.
19. Dauvois S, Danielian PS, White R, Parker MG, (1992) Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci U S A 89: 4037-4041.
20. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M, (2000) Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103: 843-852.
21. Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, et al. (2009) ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. Embo J 28: 1418-1428.
22. Hawse JR, Subramaniam M, Monroe DG, Hemmingsen AH, Ingle JN, et al. (2008) Estrogen receptor beta isoform-specific induction of transforming growth factor beta-inducible early gene-1 in human osteoblast cells: an essential role for the activation function 1 domain. Mol Endocrinol 22: 1579-1595.
23. Ballman KV, Grill DE, Oberg AL, Therneau TM, (2004) Faster cyclic loess: normalizing RNA arrays via linear models. Bioinformatics 20: 2778-2786.